Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis

Published on 03 May 2017
Last Updated on 18 Jan 2021

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Golimumab 50 mg/0.5 ml and 100 mg/ml pre-filled syringes in line with their registered indications for treating adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and ulcerative colitis.

Subsidy status

Golimumab 50mg/0.5ml and 100 mg/ml pre-filled syringes are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. 

Golimumab should be used in line with the clinical criteria in the checklists for MAF applications for anti-TNFα biologics.

MAF subsidy does not apply to golimumab 12.5mg/1ml concentrate solution for infusion formulation.

Golimumab for treating RA, PsA, AS, NR axial spondyloarthritis and UC (updated 18 Jan 2021) [PDF, 179 KB]